125 related articles for article (PubMed ID: 33947633)
21. Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma.
Chen M; Wang Z; Fang X; Yao Y; Ren Q; Chen Z; Tian Y; Pan F; Li X; Li Z; Cai Q; Huang H; Lin T
Cancer Biol Med; 2021 Aug; 18(3):833-40. PubMed ID: 35979854
[TBL] [Abstract][Full Text] [Related]
22. Survival of children with endemic Burkitt lymphoma in a prospective clinical care project in Uganda.
McGoldrick SM; Mutyaba I; Adams SV; Larsen A; Krantz EM; Namirembe C; Mooka P; Nabakooza S; Ndagire M; Mubiru K; Nabwana M; Nankinga R; Gerdts S; Gordon-Maclean C; Geriga F; Omoding A; Sessle E; Kambugu J; Uldrick TS; Orem J; Casper C
Pediatr Blood Cancer; 2019 Sep; 66(9):e27813. PubMed ID: 31157502
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Zayac AS; Evens AM; Danilov A; Smith SD; Jagadeesh D; Leslie LA; Wei C; Kim SH; Naik S; Sundaram S; Reddy N; Farooq U; Kenkre VP; Epperla N; Blum KA; Khan N; Singh D; Alderuccio JP; Godara A; Yazdy MS; Diefenbach C; Rabinovich E; Varma G; Karmali R; Shao Y; Trabolsi A; Burkart M; Martin P; Stettner S; Chauhan A; Choi YK; Straker-Edwards A; Klein A; Churnetski MC; Boughan KM; Berg S; Haverkos BM; Orellana-Noia VM; D'Angelo C; Bond DA; Maliske SM; Vaca R; Magarelli G; Sperling A; Gordon MJ; David KA; Savani M; Caimi P; Kamdar M; Lunning MA; Palmisiano N; Venugopal P; Portell CA; Bachanova V; Phillips T; Lossos IS; Olszewski AJ
Haematologica; 2021 Jul; 106(7):1932-1942. PubMed ID: 33538152
[TBL] [Abstract][Full Text] [Related]
24. Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.
Park YH; Kim WS; Kang HJ; Na II; Ryoo BY; Yang SH; Lee SS; Uhm JE; Kim K; Jung CW; Park K; Ko YH
Ann Hematol; 2006 May; 85(5):285-90. PubMed ID: 16518604
[TBL] [Abstract][Full Text] [Related]
25. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%.
Mohamedbhai SG; Sibson K; Marafioti T; Kayani I; Lowry L; Goldstone AH; Linch DC; Ardeshna KM
Br J Haematol; 2011 Jan; 152(2):175-81. PubMed ID: 21092025
[TBL] [Abstract][Full Text] [Related]
26. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.
Montoto S; Wilson J; Shaw K; Heath M; Wilson A; McNamara C; Orkin C; Nelson M; Johnson M; Bower M; Cwynarski K
AIDS; 2010 Mar; 24(6):851-6. PubMed ID: 20124971
[TBL] [Abstract][Full Text] [Related]
27. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
28. Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial.
Phillips EH; Burton C; Kirkwood AA; Barrans S; Lawrie A; Rule S; Patmore R; Pettengell R; Ardeshna KM; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC; McMillan AK
EJHaem; 2020 Jul; 1(1):133-141. PubMed ID: 35847742
[TBL] [Abstract][Full Text] [Related]
29. HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era.
Rodrigo JA; Hicks LK; Cheung MC; Song KW; Ezzat H; Leger CS; Boro J; Montaner JS; Harris M; Leitch HA
Adv Hematol; 2012; 2012():735392. PubMed ID: 22190945
[TBL] [Abstract][Full Text] [Related]
30. [Long term efficacy of COPADM regimen in the treatment of 20 patients with Burkitt lymphoma].
Yang D; Wang P; Chen J; Li CX; Zhang Y; Chen XC; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):645-649. PubMed ID: 30180465
[No Abstract] [Full Text] [Related]
31. Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels.
Kim HD; Cho H; Kim S; Lee K; Kang EH; Park JS; Park CS; Huh J; Ryu JS; Lee SW; Yoon DH; Kim SJ; Ko YH; Kim WS; Suh C
Cancer Res Treat; 2021 Jul; 53(3):847-856. PubMed ID: 33332932
[TBL] [Abstract][Full Text] [Related]
32. [Long-term clinical outcome of children and adolescents with Burkitt's lymphoma treated with rituximab combined with modified NHL-BFM-90 regimen].
Li YX; Yin QS; Ai H; Mi RH; Zhang LN; Li YF; Wei XD; Song YP
Zhonghua Yi Xue Za Zhi; 2019 Feb; 99(8):605-610. PubMed ID: 30818930
[No Abstract] [Full Text] [Related]
33. [Comparison of the efficacy of CCCG-97 and BFM-90 protocols in the treatment for children with mature B-cell non-Hodgkin's lymphoma].
Meng JH; Gao YJ; Lu FJ; Zhai XW; Wang HS; Li J
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):222-7. PubMed ID: 22780979
[TBL] [Abstract][Full Text] [Related]
34. Low-intensity therapy in adults with Burkitt's lymphoma.
Dunleavy K; Pittaluga S; Shovlin M; Steinberg SM; Cole D; Grant C; Widemann B; Staudt LM; Jaffe ES; Little RF; Wilson WH
N Engl J Med; 2013 Nov; 369(20):1915-25. PubMed ID: 24224624
[TBL] [Abstract][Full Text] [Related]
35. [Primary small intestinal Burkitt lymphoma treated with rituximab-combined CODOX-M/IVAC therapy without surgical resection].
Mizutani M; Umino A; Taniguchi M; Tamaki S; Tanigawa M; Tsuji K
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1229-32. PubMed ID: 24047786
[TBL] [Abstract][Full Text] [Related]
36. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
Roschewski M; Dunleavy K; Abramson JS; Powell BL; Link BK; Patel P; Bierman PJ; Jagadeesh D; Mitsuyasu RT; Peace D; Watson PR; Hanna WT; Melani C; Lucas AN; Steinberg SM; Pittaluga S; Jaffe ES; Friedberg JW; Kahl BS; Little RF; Bartlett NL; Fanale MA; Noy A; Wilson WH
J Clin Oncol; 2020 Aug; 38(22):2519-2529. PubMed ID: 32453640
[TBL] [Abstract][Full Text] [Related]
37. Burkitt and Burkitt-Like Lymphomas: a Systematic Review.
Saleh K; Michot JM; Camara-Clayette V; Vassetsky Y; Ribrag V
Curr Oncol Rep; 2020 Mar; 22(4):33. PubMed ID: 32144513
[TBL] [Abstract][Full Text] [Related]
38. Malawi pilot study of Burkitt lymphoma treatment.
Hesseling PB; Broadhead R; Molyneux E; Borgstein E; Schneider JW; Louw M; Mansvelt EP; Wessels G
Med Pediatr Oncol; 2003 Dec; 41(6):532-40. PubMed ID: 14595710
[TBL] [Abstract][Full Text] [Related]
39. In the South African setting, HIV-associated Burkitt lymphoma is associated with frequent leukaemic presentation, complex cytogenetic karyotypes, and adverse clinical outcomes.
Opie J; Antel K; Koller A; Novitzky N
Ann Hematol; 2020 Mar; 99(3):571-578. PubMed ID: 31955214
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates - A multicenter cohort study.
Silva WFD; Garibaldi PMM; Rosa LID; Bellesso M; Clé DV; Delamain MT; Rego EM; Pereira J; Rocha V
Leuk Res; 2020 Feb; 89():106287. PubMed ID: 31864677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
